Kishore R. Sakharkar – författare

Over the past decade, genome sequencing projects and the associated efforts have facilitated the discovery of several novel disease targets and the approval of several innovative drugs. To further exploit this data for human health and disease, there is a need to understand the genome data itself in detail, discover novel targets, understand their role in physiological pathways and associated diseases, with the aim to translate these discoveries to clinical and preventive medicine. It is equally important to understand the labors and limitations in integrating clinical phenotypes with genomic, transcriptomic, proteomic and metabolomic approaches. T

Understanding the molecular mechanisms of cancer is the key for transforming cancer medicine. A substantial proportion of human genes show alternative splicing and mis-regulation of Pre-mRNA splicing is seen in several cancers.This book further investigates these matters. The first few chapters provide an update on the role of genomics in understanding alternative splicing, and targets in cancer pathogenesis. Advances and prospects in applications of nanotechnology for cancer prevention, detection and treatment are a promising field of research. The subsequent chapters provide insights on how nanotechnology-based therapeutics are moving towards revolutionizing cancer and infectious disease treatment by minimizing toxicity and facilitating targeted delivery of drugs. Technical topics discussed in the book include: • Alternative splicing and cancer• Cancer imaging• Nanomaterials in infectious diseases• Nanomedicine in oxidative stress and cancer• Nanoparticle based drug delivery systems

Over the past decade, genome sequencing projects and the associated efforts have facilitated the discovery of several novel disease targets and the approval of several innovative drugs. To further exploit this data for human health and disease, there is a need to understand the genome data itself in detail, discover novel targets, understand their role in physiological pathways and associated diseases, with the aim to translate these discoveries to clinical and preventive medicine. It is equally important to understand the labors and limitations in integrating clinical phenotypes with genomic, transcriptomic, proteomic and metabolomic approaches. T